Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 2/20 | 0.34 |
| ▸ | FNTB | P49356 | 2/20 | 0.34 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275642 | 0.83 | PDE3B (0.37) | FNTAFNTBPGGT1BKCNH2 | |
| SCHEMBL10275681 | 0.80 | BRD4 (0.38) | FNTAFNTBKCNH2 | |
| SCHEMBL10276009 | 0.73 | PDE3B (0.36) | FNTAFNTBPGGT1BKCNH2 | |
| SCHEMBL10275945 | 0.73 | AR (0.34) | FNTAFNTBPGGT1BKCNH2 | |
| SCHEMBL10276352 | 0.71 | PDE3B (0.36) | — | |
| SCHEMBL10276335 | 0.71 | PDE3B (0.36) | FNTAFNTBPGGT1B | |
| SCHEMBL10275675 | 0.70 | KCNH2 (0.33) | FNTAFNTBPGGT1BKCNH2EGFR | |
| SCHEMBL10276045 | 0.70 | APP (0.35) | — | |
| SCHEMBL10276696 | 0.69 | KIF11 (0.34) | KCNH2 | |
| SCHEMBL10276326 | 0.67 | CYP3A4 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | FNTA 3998/4885FNTB 3608/4885PGGT1B 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.